Core technology of N-Gene is based on compounds in the family of hydroxylamine derivatives proven to restore, via modulating stress response, disturbed signaling pathways thereby treating the root cause of a wide range of disorders.
BGP-15 has been extensively investigated in preclinical models of diseases commonly related to targeted mechanisms of the compound.
N-Gene has completed three POC/POE human clinical trials in insulin resistance related therapeutic indications.
An international group of scientists, led by Prof Gordon Lynch at the University of Melbourne, Australia, have shown that increasing the amount of HSP72 can have a beneficial effect in a mouse model of Duchenne muscular dystrophy.
BGP-15 is eligible for Data Exclusivity protection for 5 years in the US and up to 10 years in the EU, in the diabetes indication, and has been awarded orphan status in Duchenne Muscular Dystrophy.